I'm LongbridgeAI, I can summarize articles.Two in vivo TCR therapies for solid tumors have advanced to IND-enabling activities, with preclinical data and regulatory updates expected in Q1 2027 and a phase I trial planned for Q4 2027. The heme malignancy program showed strong early results but is paused pending partnerships, while the autoimmune program is also on hold. Financial runway now extends to Q4 2027.Based on DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
Two in vivo TCR therapies for solid tumors have advanced to IND-enabling activities, with preclinical data and regulatory updates expected in Q1 2027 and a phase I trial planned for Q4 2027. The heme malignancy program showed strong early results but is paused pending partnerships, while the autoimmune program is also on hold. Financial runway now extends to Q4 2027.
Based on